VolitionRX (NYSEAMERICAN:VNRX) Posts Quarterly Earnings Results, Beats Estimates By $0.18 EPS

Posted by Danessa Lincoln on Nov 13th, 2026

VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) released its quarterly earnings results on Thursday. The medical research company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.18, Zacks reports. The business had revenue of $1.61 million during the quarter, compared to the consensus estimate of $0.71 million.

VolitionRX Stock Performance

Shares of NYSEAMERICAN VNRX opened at $0.18 on Friday. VolitionRX has a 1-year low of $0.16 and a 1-year high of $7.90. The stock’s 50-day moving average is $0.23 and its two-hundred day moving average is $1.95.

Analysts Set New Price Targets

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRX in a report on Monday, August 17th. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.00.

Get Our Latest Analysis on VolitionRX

VolitionRX Company Profile

(Get Free Report)

VolitionRx Limited is a biotechnology company developing blood-based diagnostic tests intended to support the early detection and management of disease. Its technology platform, Nu.Q, analyzes nucleosomes—small structures released into the bloodstream when cells die—to identify biological signals associated with cancer and other conditions. The company’s products and development programs serve human and veterinary health markets. Its Nu.Q Vet platform is designed to help veterinarians screen for and monitor cancer in companion animals, while the company is also developing Nu.Q-based applications for human cancer, infectious diseases, and other medical conditions.